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Abstract
The synthesis of antimicrobial thymol/carvacrol-loaded polythioether nanoparticles (NPs) via a 
one-pot, solvent-free miniemulsion thiol-ene photopolymerization process is reported. The active 
antimicrobial agents, thymol and carvacrol, are employed as “solvents” for the thiol-ene monomer 
phase in the miniemulsion to enable facile high capacity loading (≈50% w/w), excellent 
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encapsulation efficiencies (>95%), and elimination of all postpolymerization purification 
processes. The NPs serve as high capacity reservoirs for slow-release and delivery of thymol/
carvacrol-combination payloads that exhibit inhibitory and bactericidal activity (>99.9% kill 
efficiency at 24 h) against gram-positive and gram-negative bacteria, including both saprophytic 
(Bacillus subtilis ATCC 6633 and Escherichia coli ATCC 25922) and pathogenic species (E. coli 
ATCC 43895, Staphylococcus aureus RN6390, and Burkholderia cenocepacia K56-2). This report 
is among the first to demonstrate antimicrobial efficacy of essential oil-loaded nanoparticles 
against B. cenocepacia – an innately resistant opportunistic pathogen commonly associated with 
debilitating respiratory infections in cystic fibrosis. Although a model platform, these results point 
to promising pathways to particle-based delivery of plant-derived extracts for a range of 
antimicrobial applications, including active packaging materials, topical antiseptics, and innovative 
therapeutics.
1. Introduction
Microbial threats, particularly multidrug-resistant (MDR) bacterial strains and other 
emerging pathogens, are greatly impacting public health, burdening healthcare systems, and 
have potential to disrupt socioeconomic infrastructures in both developing and industrialized 
nations. In the United States alone, the Center for Disease Control estimates at least two 
million illnesses and 23 000 deaths are attributed to multidrug-resistant bacterial infections 
each year. Annually, these cases account for ≈$20 billion in excess health care costs and up 
to $35 billion in lost productivity due to sick leave and hospitalizations.[1] While 
Staphylococcus aureus and Pseudomonas aeruginosa tend to dominate the MDR discussion, 
other microorganisms, such as Burkholderia cepacia complex (Bcc), have emerged as 
opportunistic pathogens with significant clinical importance in persons with cystic fibrosis 
(CF).[2] Pulmonary colonization with Burkholderia cenocepacia, the most common isolate 
of the 18 member Bcc, results in severe respiratory infections in persons with CF and is 
associated with high morbidity and mortality rates.[3] Effective treatments for B. 
cenocepacia infections are rare, as these bacteria exhibit high intrinsic resistance to most 
antibiotics.[4] In general, the MDR microbial threat extends far beyond the effect on humans, 
and additionally impacts animal agriculture and veterinary medicine. The continuous 
emergence of MDR pathogens and scarcity of new antimicrobial drug scaffolds in the 
pharmaceutical discovery pipeline have led to growing interest in natural, plant-derived 
extracts as alternatives to synthetic antibiotics.[5] In this direction, essential oils (EOs) – 
typically complex extracts from aromatic plants comprising mixtures of aldehydes, terpenes, 
and phenols – are well known to exhibit broad spectrum biological and antimicrobial 
activity.[6,7] With many EOs identified as “Generally Regarded as Safe,” these extracts have 
been actively explored and continue to garner interest as food preservatives and packaging 
constituents,[8,9] textile fragrances,[10] pesticides,[11] and other antimicrobial therapeutic 
applications.[12–14]
Monoterpene phenol isomers, carvacrol and thymol, are major constituents of EOs extracted 
from oregano, thyme, and other plants belonging to the Lamiaceae family. These isomers 
show antiviral, antifungal, and broad spectrum antibacterial properties against both gram-
negative and gram-positive bacteria, including MDR and biofilm forming 
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microorganisms.[15,16] In one promising example, EO extracts containing carvacrol and 
thymol as primary constituents were shown to inhibit the growth of several environmental 
and clinical bacterial strains belonging to the B. cepacia complex.[17] The broad spectrum of 
activity of these isomers has been attributed to multiple modes of toxicity; however, the 
primary site of toxicity is the cell membrane.[16] In general, these hydrophobic isomers act 
by partitioning into the cytoplasmic membrane leading to increased permeability, depletion 
of proton gradients, and subsequent disruption of adenosine triphosphate (ATP) synthesis. 
The collapse of the proton motive force and depletion of the ATP pool eventually lead to cell 
death.
A major challenge for the practical application of carvacrol and thymol as antimicrobial 
agents stems from the hydrophobicity (poor water solubility), volatility, and instability of 
these EO constituents. Poor water solubility, in particular, limits the bioavailability of these 
compounds and significantly lowers their biological and antimicrobial activity, whereas 
volatility is problematic for achieving sustained release and controlled delivery. To address 
these challenges, a variety of approaches have been reported to encapsulate hydrophobic EO 
constituents as colloidal systems, including oil-in-water emulsions, microemulsions, and 
nanoemulsions; molecular inclusion complexes; lipid-based carriers (e.g., liposomes and 
solid lipid nanocapsules);[18] and polymer-based carriers (e.g., films, micro/nanocapsules, 
and nanoparticles).[5,19,20] Polymer nanoparticles (PNPs) are advantageous in that they offer 
a highly flexible delivery platform for antimicrobial applications, where nanoparticle 
properties (e.g., morphology, bulk/surface composition, and size) are readily tunable using a 
variety of synthetic approaches.[21–24] In turn, these tunable PNP properties dictate 
important features such as particle stability, surface interactions, and EO loading and release 
kinetics. In this direction, researchers have successfully incorporated carvacrol, thymol, and 
other phenolic EO constituents into various PNP matrices (chitosan,[25] poly(lactide-co-
glycolide),[26,27] methylcellulose,[28] and zein[29]) via emulsification-evaporation,[26,27] 
emulsification-solvent exchange,[28] and nanoprecipitation[29] methods. While these 
examples demonstrate facile fabrication, encapsulation, and exhibit antimicrobial activity, 
many suffer several deficiencies such as low EO loading (i.e., 3% w/w carvacrol in chitosan 
matrix), poor EO encapsulation efficiencies (e.g., 14%–31% carvacrol-in-water emulsion 
and ionic gelation of chitosan),[30] use of organic solvents during encapsulation (acetone, 
ethanol, dichloromethane),[26,29] and burst release profiles of EO.[26,27]
Miniemulsion polymerization is ideally suited for encapsulation of hydrophobic payloads 
(e.g., lipophilic drugs, pigments, fragrances, inorganic nanomaterials, and polymers) with 
high loading and encapsulation efficiencies,[31–33] but has received little attention for 
sequestration and delivery of essential oils – particularly toward antimicrobial applications. 
Miniemulsion polymerizations are described as aqueous dispersions of small, narrowly 
distributed monomer droplets stabilized against Ostwald ripening and collisional degradation 
by addition of an appropriate surfactant and costabilizer. Monomer droplets ranging in size 
from 50–500 nm are attained via high shear mixing – typically either high-pressure 
homogenization or ultrasonic processing – and subsequently serve as discrete nanoreactors 
for the formation of polymer nanoparticles upon polymerization. Since mass transport 
between monomer droplets is suppressed, encapsulation of hydrophobic materials requires a 
straightforward addition of the desired material to the organic phase prior to shear mixing. 
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Thus, encapsulation of materials miscible with the monomer phase provides polymer 
nanoparticles with the payload dispersed throughout the polymer matrix (whereas 
immiscible materials provide a route to nanocapsules).[33] Recently, we and others have 
reported thiol-ene[34–37] and thiol-alkyne[38,39] polymerization in miniemulsion as a facile 
platform for the synthesis of crosslinked polythioether nanoparticles with tunable particle 
sizes, tailorable network properties, and clickable surface functionality. More importantly, 
we demonstrated the ability to encapsulate hydrophobic inorganic nanoparticles within the 
polythioether matrix with high efficiency without sacrificing the rapid polymerization 
kinetics and high conversions provided by the thiol-mediated photopolymerization process.
Herein, we report a facile, one-pot approach to encapsulate monoterpene phenols (carvacrol/
thymol) within polythioether nanoparticles as a model, sustained-release antimicrobial 
platform. We employ thiol-ene photopolymerization in miniemulsion for rapid nanoparticle 
synthesis, where carvacrol and thymol serve as miscible compatibilizers in the monomer 
phase enabling solvent-free encapsulation with high loading capacities (33%–66% w/w, EO 
relative to the NP) and excellent encapsulation efficiencies (>95%). The absence of solvent 
and use of a polymerizable surfactant eliminate the need for any postpolymerization 
purification steps. Release studies reveal the polythioether nanoparticles function as 
sustained-release reservoirs for carvacrol/thymol – discharging less than 4% of the payload 
over 24 h. The thymol/carvacrol-loaded (TCNPs) nanoparticles show effective antimicrobial 
activity (>99.9% kill efficiency at 24 h) against gram-positive (Bacillus subtilis and 
Staphylococcus aureus) and gram-negative (Escherichia coli and Burkholderia cenocepacia) 
bacteria. Considering the innate resistance of the bacterial strain, the high efficacy of TCNPs 
against Burkholderia cenocepacia is particularly significant, and to our knowledge, 
represents the first demonstration of antibacterial efficacy against B. cenocepacia using 
thymol/carvacrol-loaded polymer nanoparticles.
2. Results and Discussion
2.1. Synthesis and Characterization of Essential Oil Encapsulated Nanoparticles
Polythioether NPs loaded with various ratios of carvacrol/thymol were synthesized via thiol-
ene photopolymerization in miniemulsion according to Figure 1a. NPs were prepared by 
dispersing the organic phase, comprising diallyl phthalate (DAP), glycol di(3-
mercaptopropionate) (GDMP), pentaerythritol tetra(3-mercaptopropionate) (PETMP), and 
carvacrol/thymol into deionized water containing surfactant via probe ultrasonication for 25 
min (Figure 1b). The full details for the miniemulsion formulation are given in Table S1 
(Supporting Information). The monomer droplets were then photopolymerized by exposure 
to UV light (λmax 365 nm). Control NPs (without carvacrol/thymol) were similarly prepared 
using butyl acetate as a diluent for the organic phase. After ultrasonication and 
photopolymerization, aliquots were removed and analyzed via proton nuclear magnetic 
resonance spectroscopy (1H NMR) (Figure S1, Supporting Information) in D2O. The 
disappearance of the peaks attributed to the thiol (–CH2CH2–SH, 2.62–2.83 ppm) and 
alkene (5.07–5.45, 5.87–6.10 ppm) from the monomers, and broadening of other peaks 
indicated the thiol-ene photopolymerization proceeded to high conversion. Additionally, 
Raman spectroscopy of freshly emulsified nanoparticles prior to and after UV 
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polymerization showed the disappearance of SH (2580 cm−1) and alkene stretches (1640–
1680 cm−1) (Figure S2, Supporting Information). The ability to achieve high thiol-ene 
monomer conversion in the presence of phenolic functional groups is in good agreement 
with our previous work.[38,40,41] At near quantitative conversions, crosslink density (0.168 × 
10−3 mol cm−3) of the polythioether NPs was estimated from the rubbery plateau storage 
modulus (1.25 MPa, Tg −12.1 °C, Figure S3, Supporting Information) of the base thiol-ene 
resin (i.e., GDMP+PETMP+diallyl phthalate prepared at identical stoichiometric ratios used 
in the miniemulsions) at Tg + 40 °C according to the theory of rubber elasticity.[42] To 
eliminate surfactant leaching, Hitenol BC-20 was employed as a polymerizable surfactant to 
covalently incorporate the surfactant into the thiol-ene network (discussed further in the 
antimicrobial section). A series of exploratory NP syntheses were conducted, in which the 
concentration of Hitenol BC-20 (Figure S4a, Supporting Information) and organic weight 
fraction (Figure S4b, Supporting Information) were independently varied, to identify 
conditions to provide acceptable NP size and size distributions. A 4.5 wt% organic phase 
and 70 × 10−3 M Hitenol BC-20 were identified as optimum parameters; these conditions 
provided pure carvacrol-loaded NPs (CNPs), thymol/carvacrol-loaded NPs (TCNPs), and 
control NPs with mean particle sizes of 148 ± 24 (PDI: 0.560), 147 ± 19 (PDI: 0.387), and 
183 ± 19 nm (PDI: 0.473), respectively, as determined by dynamic light scattering (DLS). 
We note that the reported std. dev. values represent the deviation in the average particle size 
obtained from a minimum of three separate syntheses. A representative transmission 
electron microscopy (TEM) image for TCNPs loaded with a 0.75:1 T:C ratio (Figure 1c) 
showed spherical particles with sizes in good agreement with DLS analysis. TEM for the 
control NPs and CNPs are shown in Figure S5a,b, respectively. The salient feature of this 
synthetic approach is that the carvacrol/thymol constituents serve as the “solvent” for the 
organic phase in the miniemulsion process. This route enabled a high loading capacity of 
thymol/carvacrol within the NPs (between 33% and 66% w/w, EO/NP) with high 
encapsulation efficiencies (>95% by GC-MS), eliminated the need for an organic solvent 
during NP synthesis, and provided a one-pot approach to EO encapsulation without any 
postpolymerization purification processes (e.g., no freeze drying, evaporation, and extraction 
processes were required). Thus, the NP dispersions obtained from the previously described 
synthetic approach were used directly for the antimicrobial studies detailed below.
2.2. Loading and Release of Thymol and Carvacrol
Next, we investigated the kinetics of carvacrol and carvacrol/thymol mixtures released from 
polythioether NPs into water. The amount of essential oil released was quantified by 
measuring the concentration of carvacrol/thymol available in water via GC-MS at 0, 4, 8, 
and 12 h. Figure 2a shows the release data for CNPs (synthesized at 33% w/w C/NP) and 
TCNPs (synthesized with 47% w/w TC/NP, 0.75:1 T:C). The EOload data points represent the 
total amount of carvacrol (16 ± 0.7 mg mL−1) and thymol/carvacrol (25 ± 5 mg mL−1) 
loaded into the NPs during miniemulsion photopolymerization, and are in good agreement 
with initial formulations for each type of NP. The ratio of the time 0 and EOload 
concentrations represents the encapsulation efficiency for the miniemulsion process, i.e., 
≈96.9% for TCNPs and 96.8% for CNPs. Thus, the concentration of EO within the 
nanoparticles is up to 20 times higher than the reported solubility limits for thymol (0.85 mg 
mL−1) and carvacrol (1.25 mg mL−1) at 20 °C.[43] As shown in Figure 2a, the concentration 
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of EO released from the NPs in water was relatively constant over 24 h, where TCNPs and 
CNPs reached plateau concentrations between 0.7–0.9 mg mL−1 and 0.5–0.6 mg mL−1, 
respectively. These concentrations correspond to less than 4% release of the total EO 
payload over 24 h, (Figure 2b) and approach the solubility limit of thymol and carvacrol in 
water at 20 °C. These results suggest that the polythioether nanoparticles effectively serve as 
a reservoir for the hydrophobic carvacrol and thymol compounds. This “reservoir effect” 
enables extended delivery of EO constituents into the bulk aqueous phase, where the 
solubility limit of the relatively insoluble compounds ultimately dictates the aqueous-phase 
equilibrium concentration.
2.3. Antimicrobial Properties
Antimicrobial activity of the EO-containing NPs was evaluated against a panel of gram-
positive and gram-negative bacteria that included both saprophytic (B. subtilis ATCC 6633 
and E. coli ATCC 25922) and pathogenic species (E. coli ATCC 43895 [serotype O157:H7], 
S. aureus RN6390, and B. cenocepacia K56-2). Our preliminary experiments revealed that 
control NPs prepared using either sodium dodecyl sulfate or cetyltrimethylammonium 
bromide as surfactant exhibited antimicrobial activity, presumably due to surfactant 
leaching. Thus, we chose Hitenol BC-20 – a commercially available polymerizable 
surfactant – for further experiments, as it exhibited no measurable antimicrobial activity in 
zone of inhibition (ZOI) experiments at the concentration used in NP synthesis (70 × 10−3 M 
Figure 3a; 140 × 10−3 M Figure S6, Supporting Information). More importantly, control NPs 
prepared with Hitenol BC-20 showed no measureable ZOI against all five bacteria (Figure 
3b). Initially, we evaluated the antimicrobial activity of NPs containing pure carvacrol (33% 
w/w, carvacrol relative to NP) and various ratios of thymol:carvacrol (Treatment I – 66% 
w/w, 3:1 T:C; Treatment II – 55% w/w, 1.5:1 T:C; and Treatment III – 47% w/w, 0.75:1) 
against E. coli ATCC 25922, S. aureus RN6390, and B. subtilis ATCC 6633 (Figure S7, 
Supporting Information). Since thymol is a solid at room temperature (mp 49–51 °C), 
thymol-loaded NPs were difficult to synthesize using a solvent-free approach and were not 
actively pursued in this work. Previous reports have shown that combinations of thymol and 
carvacrol exhibit higher antimicrobial activity than each individual constituent,[16] thus, 
carvacrol-loaded NPs were evaluated via ZOI only as a comparison to NPs loaded with 
combinations of thymol/carvacrol. Interestingly, all treatments with NPs containing thymol/
carvacrol showed similar zones of inhibition (Figure S7, Supporting Information), thus 
treatment III, with the lowest overall thymol/carvacrol loading, was chosen for the 
experiments discussed hereafter. From this point forward, the acronym TCNP will refer to 
nanoparticles loaded with 47% w/w, 0.75:1 T:C (treatment III). Figure 3c,d shows the results 
of well diffusion assays for CNPs and TCNPs against the full panel of bacteria. As shown in 
Figure 3c, CNPs exhibited moderate activity against all bacteria (ZOI 1–2 mm). As expected, 
TCNPs were consistently more effective than CNPs, as indicated by the larger ZOIs shown in 
Figure 3d. TCNPs inhibited the growth of all five bacteria, including S. aureus (2 mm ZOI) 
and B. cenocepacia (3 mm ZOI) that are known to exhibit high intrinsic resistance to 
conventional antibiotics. Bacillus subtilis (6 mm ZOI) was the most susceptible species to 
the TCNP treatment.
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The antimicrobial activity of TCNPs was further evaluated via determination of the minimum 
inhibitory concentration (MIC). The MIC is defined as the lowest concentration of an 
antimicrobial agent that inhibits the growth of a microorganism following an overnight 
incubation period. We adopted a modified broth microdilution method to determine MICs 
for NP-loaded thymol/carvacrol.[44] We also spot-plated bacteria that were incubated with 
NPs to check for possible bacteriostatic effects. While MIC assays are reputable for 
accuracy and standardized comparison across numerous antibiotics, the conventional MIC 
output presents a challenge for hydrophobic antibiotics encapsulated in polymer 
nanoparticles – and is particularly problematic for NP delivery systems that function via the 
“reservoir effect.” As a result of the “reservoir effect,” the concentration loaded in the 
nanoparticle may be orders of magnitude greater than the concentration delivered to the 
bacteria during the time frame of the MIC assay. For example, the loaded concentration of 
thymol/carvacrol in TCNPs was determined to be 25 000 μg mL−1 by GC-MS. These thymol/
carvacrol loading levels are up to 100-fold higher than reported MIC values for E. coli 
ATCC 25922 (MICcarvacrol: 225 μg mL−1, MICthymol: 225 μg mL−1) and S. aureus 
(MICcarvacrol: 450 μg mL−1, MICthymol: 225 μg mL−1);[45] however, our release studies show 
that carvacrol and thymol are delivered to the bulk aqueous phase at a relatively constant 
concentration of 500–900 μg mL−1 over 24 h. Following the precedent of Langer and co-
workers,[46] who previously noted the difficulty in defining the MIC for antibiotic-loaded 
nanoparticles, we report concentrations as the total EO concentration within the NP at the 
beginning of the treatment to identify the MIC. While the loaded concentrations grossly 
overestimate the MIC value relative to a conventional definition, we reasoned this route of 
reporting was the most useful and conservative measure of NP-loaded antimicrobial efficacy. 
Additionally, we calculated the nanoparticle number density (number of particles per mL) to 
estimate the number of NPs delivered in each experiment as an alternate MIC output value, 
with the caveat that the number density is based on the average particle diameter of a 
polydisperse nanoparticle population. Nonetheless, number density MIC provides a point of 
comparison among the various bacteria investigated in this paper. Figure 4 shows the results 
from the viability assays used to determine the MICs for TCNPs. In general, the growth of all 
five bacteria included in this study was completely inhibited upon exposure to TCNPs loaded 
at 25 000 μg mL−1 (1010 nanoparticles) in a 50 μL broth volume, which translated to ≈105 
NPs per bacterial cell. B. subtilis was the most susceptible species, and was completely 
inhibited at TCNPs loaded at 2 500 μg mL−1 (109 nanoparticles, ≈104 NPs per cell). The 
MIC values are in good agreement with the previously described results of agar well 
diffusion tests.
We also investigated the kill kinetics for the panel of bacteria incubated with TCNPs using 
live/dead and terminal dilution assays. Initially, the kill kinetics of TCNPs against B. subtilis 
ATCC 6633 and E. coli ATCC 25922 were probed using a live/dead cell viability assay, 
which stains “dead” bacteria red upon cell membrane damage and uptake of propidium 
iodide. As shown in Figure 5a,b a large number of viable bacterial cells (stained green) were 
observed for the B. subtilis and E. coli control samples, respectively. Incubation of TCNPs 
with B. subtilis for 15 min yielded an apparent 50:50 live/dead ratio, whereas 30 min 
resulted in mostly dead bacteria (Figure 5a). For E. coli ATCC 25922, the 50:50 live/dead 
ratio was observed after two hours of incubation with TCNPs, and most bacteria stained dead 
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after 8 h of incubation (Figure 5b). To quantify the kill kinetics for all five bacteria, we used 
a terminal dilution assay. Figure 6a shows the log reduction in the bacteria count as a 
function of incubation time with ≈1011 TCNPs. The log CFU reductions at 48 h are reported 
as % kill values in Figure 6b. In agreement with our previous ZOI data, B. subtilis ATCC 
6633 showed the highest susceptibility to the TCNP treatment with 4.3 and 7.1 log 
reductions observed at 12 and 24 h, respectively. The log reductions for E. coli O157:H7 
(ATCC 43895) were 3.5 at 12 h and 7 at 24 h — results that translate into a kill efficacy of 
>99.99%. The viability of E. coli ATCC 25922 declined at a slower rate than E. coli 
O157:H7, however, the 48 h exposure to TCNPs ultimately killed >99.99% of the bacteria. 
Incubation of TCNPs with B. cenocepacia K56-2 produced 3.9 and 6.2 log reductions at 12 
and 24 h, respectively. The kill kinetics and high susceptibility (over 99.99% efficacy at 24 
h) of B. cenocepacia to the TCNPs is of particular interest, as these bacteria have very high 
innate resistance to a wide range of antibiotics and biocides.[47] With a 3.6 log reduction, S. 
aureus RN6390 was the only species that maintained viability after 24 h incubation with 
TCNPs. However, a 6.3 log reduction, or >99.99 % kill efficacy for S. aureus was ultimately 
attained at 48 h.
Finally, insight into the antimicrobial mechanism was investigated by visualizing the 
microbial structure of B. subtilis ATCC 6633 and E. coli ATCC 25922 before and after 
prolonged contact with TCNPs using electron microscopy. Prior to exposure to TCNPs, TEM 
of both microbes showed intact cell structure (Figure 7, control). After exposure with TCNPs, 
distinct indication of damage to the cell envelope (diffuse membrane, cellular debris) and 
loss of flagella were visible in both E. coli ATCC 25922 (Figure 7a) and B. subtilis ATCC 
6633 (Figure 7b). Additionally, the scanning electron microscopy (SEM) image of B. 
subtilis after 24 h exposure to inhibitory concentrations of TCNPs showed bacteria with 
crumpled cell envelopes and pore-like lesions, which is consistent with the collapse of the 
cell structure (Figure 7c). These results are consistent with previously reported postulates 
that identify the cell membrane as the primary site of toxicity for carvacrol/thymol.[16]
3. Conclusion
We have reported a one-pot, solvent-free miniemulsion photopolymerization process for the 
synthesis of thymol/carvacrol-loaded polythioether nanoparticles. Using the thymol/
carvacrol payload directly as a diluent for the monomer phase in the presence of a 
polymerizable surfactant provided the active NPs without any postsynthetic purification. The 
NPs serve as high capacity reservoirs for slow-release and delivery of thymol/carvacrol-
combination payloads that exhibit inhibitory and bactericidal activity (>99.9% kill efficiency 
at 24 h) against gram-positive (Bacillus subtilis and Staphylococcus aureus) and gram-
negative (Escherichia coli and Burkholderia cenocepacia) bacteria. The simplicity, 
modularity, and efficacy of the essential oil encapsulation platform may combat bacteria 
with intrinsic resistance to conventional antibiotics, and is potentially adaptable for delivery 
of EOs as active packaging materials and topical antiseptics. The antimicrobial activity of 
TCNPs against inherently resistant Burkholderia cenocepacia may provide a route to 
innovative pulmonary therapeutics by appropriately engineering the nanoparticle properties; 
investigations of thymol/carvacrol-loaded NPs against B. cepacia complex biofilms — a 
challenging form of the bacteria commonly associated with cystic fibrosis — are currently 
Amato et al. Page 8
Adv Healthc Mater. Author manuscript; available in PMC 2017 June 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
underway. In this direction, we are particularly interested to exploit the simple synthetic 
modularity of this process for the design of EO-loaded biodegradable nanoparticles with 
specific surface chemistries to serve as multimode (e.g., contact biocidal, targeted NP-
bacteria interactions) antimicrobial platforms.
4. Experimental Section
Materials
GDMP and PETMP were provided by Bruno Bock. Hexadecane, ethyl acetate, sodium 
chloride, and thymol were obtained from Fisher Scientific. DAP, 4-p-methoxy phenol 
(MEHQ), and butyl acetate were acquired from Sigma-Aldrich. Other reagents were 
purchased from the following vendors: 1-hydroxycyclohexyl phenyl ketone (Irgacure 184) 
from CIBA; Hitenol BC-20 from Montello, Inc.; carvacrol from TCI America. Difco Agar, 
Mueller Hinton II agar (MHA), Mueller Hinton II broth (MHB), and Bacto Tryptone were 
from Becton, Dickinson and Company. All the materials were obtained at the highest purity 
available and used without further purification unless otherwise specified.
Characterization Methods
The size and distribution of the NPs were measured by DLS using a Microtrac Nanotrac 
Ultra NPA150 particle analyzer. Particle size and distribution were obtained using the 
Microtrac Flex software (v.10.6.1), which employs non-negatively constrained least-squares 
and cumulants analysis to obtain the intensity-weighted “z-average” mean particle size as 
the first cumulant, and the polydispersity index from the second cumulant.[48] Transmission 
electron micrographs were taken with a Zeiss 900 electron microscope operating at 50 kV 
and outfitted with a Model 785 Erlangshen ES1000 WCCD camera (Gatan). Samples were 
applied to 200 mesh copper grids (3.05 mm, 200 lines per inch square mesh, Electron 
Microscopy Sciences) coated with Formvar (5% polyvinyl formal resin). Proton (1H) NMR 
was recorded on a Bruker Acend 600 MHz spectrometer at 30 °C in D2O, using 128 scans 
and a 4.27 s relaxation delay. Optical density (OD) and fluorescence readings were 
performed in a BioTek Synergy 2 programmable microplate reader. Confocal images were 
taken using a Zeiss LSM 510 confocal laser scanning microscope. High-resolution field 
emission SEM (FE-SEM) was performed with a Zeiss SIGMA variable pressure field 
emission scanning electron Microscope operating at 10 kV in high vacuum mode. Samples 
were sputter coated with silver at instrument-reported thickness of 5 nm with a Quorum 
Emitech K550X sputter coater. Raman spectra were acquired using a high-performance 
portable Raman spectrometer (i-Raman Plus, B&W Tek Inc., Delaware, USA). The samples 
were analyzed at 100 mW, with a 785 nm diode laser and 150 s accumulation time.
General Nanoparticle Sample Preparation
Each nanoparticle synthesis was prepared in a 20 mL scintillation vial with a total volume of 
10 mL. The organic stock solutions shown in Table S1 (Supporting Information) were added 
into a vial containing a stock solution of Hitenol BC 20 and deionized water. As we 
previously reported, MEHQ serves as a radical inhibitor to suppress thermal polymerization 
during ultrasonication.[34] The samples were placed into an ice bath and sonicated using a 
Qsonica Q700 probe ultrasonicator at 25% amplitude for 25 min. The resultant 
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miniemulsions were cured for 15 min at an intensity of 185 mW cm−2 using an OmniCure 
S1000 UV light source with a 100 W mercury lamp (λmax = 365 nm, 320–500 nm filter). 
All samples were made in triplicate to ensure data reproducibility.
Preparation of Essential Oil Encapsulated Nanoparticles
Carvacrol encapsulated nanoparticles were prepared by replacing butyl acetate with 33% 
w/w carvacrol as the solvent. For nanoparticles containing a combination of thymol and 
carvacrol, 20% w/w thymol was added along with 27% w/w carvacrol. The total organic 
fraction evaluated was 4.5% w/w for all samples.
Determination of nanoparticle number density (particles per mL)
(1)
Where organic added is a known volume that can be converted into cubic nanometers
(2)
Where r is the radius (nm) determined from light scattering
(3)
The final number of particles is determined by dividing the total volume of organic by the 
volume of the average nanoparticle size (see Table S2, Supporting Information). This 
number results in particles per 10 mL (10 mL is the total volume of the emulsified solution), 
multiplication of volume added by this number results in the number of particles delivered.
Gas Chromatography–Mass Spectrometry (GC–MS) Release Study of Essentials Oil 
Nanoparticles
Freshly prepared CNPs and TCNPs were transferred in 100 mL volumetric flasks and diluted 
1:10 with deionized water. For each diluted suspension, 10 mL aliquots were removed at 0, 
4, 8, 12, and 24 h, and NPs were precipitated for 4 h at 40 000 rpm (4 °C) in a Beckman 
Coulter Optima XE ultracentrifuge. 200 μL of the supernatant was removed and extracted by 
vortexing for 30 s with 800 μL of ethyl acetate. The liquid phases were separated by 
centrifugation for 15 min at 13 000 rpm, and the organic layer was transferred to a capped 
1.5 mL GC-MS vial. To determine the amounts of EOs in the pre-emulsified organic 
monomer mixture, 450 μL of organic stock solution (carvacrol and combo) was diluted 
1:100 in ethyl acetate. All samples were placed into capped GC-MS vials and run using the 
following protocol.
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GC-MS analysis was performed on an Agilent 6890 GC/MSD equipped with an auto 
sampler and a Restek RTx-1 30 meter column. All samples and standards were analyzed 
from 1 μL injection volumes. Analysis parameters include an inlet temperature of 200 °C in 
splitless mode and a helium flow rate of 30 mL min−1 in gas saver mode. Thermal ramping 
conditions used include an initial hold at 45 °C for 4 min followed by an increase in 
temperature at 25 °C min−1 up to 140 °C with a 3 min hold at 140 °C. The temperature ramp 
continued at 2.5 °C min−1 up to 150 °C with a 3 min hold followed by a final increase at 
50 °C min−1 to 220 °C with a 7 min hold (Figure S8, Supporting Information). The method 
provided unique separation of thymol and carvacrol isomers eluting at 19.41 and 19.58 min, 
respectively (Figure S9, Supporting Information). Calibration curves for both isomers were 
prepared in ethyl acetate at 0, 200, 400, 600, 800, and 1000 ng μL−1 (Figure S10, Supporting 
Information). A representative chromatogram of extracted nanoparticles depicting the 
elution of thymol, carvacol, and hexadecane can be seen in Figure S11 (Supporting 
Information).
Evaluation of Antibacterial Activity of Nanoparticles
The antimicrobial activity of NPs was tested against several species of bacteria using a well 
diffusion method. The indicator microorganisms included Escherichia coli ATCC 25922 
(serotype O6, biotype 1), E. coli ATCC 43895 (serotype O157:H7), Staphylococcus aureus 
RN6390,[49] Bacillus subtilis subsp. spizizenii ATCC 6633, and Burkholderia cenocepacia 
K56-2 (clinical isolate from Canada).[50] The testing was done on Mueller Hinton II agar 
(MHA) plates that had been overlaid with soft agar seeded with individual bacterial strains. 
The soft agar contained (per liter): 10 g of Bacto Tryptone, 6 g of Difco agar, and 8 g of 
sodium chloride. To create an overlay, the indicator organisms were grown overnight at 
27 °C (B. subtilis) or 37 °C (E. coli, S. aureus, and B. cenocepacia) in MHB. The overnight 
cultures were diluted 1:5 with fresh MHB, and mixed with molten soft agar to achieve the 
density of ≈108 CFU mL−1. From this mixture, 4 mL aliquots were overlaid onto MHA base 
plates and allowed to completely solidify.
After solidifying of soft agar, 8 mm wells were made and their bottoms were sealed with 20 
μL of MHA. Then, 70 μL of each sample was added to the wells and allowed to freely 
diffuse into growth medium. Wells containing pure carvacrol or a mixture of carvacrol (1 g) 
and thymol (0.6 g) were used as a positive control. Negative controls contained 70 × 10−3 M 
Hitenol BC 20, or empty NPs suspended in butyl acetate. The plates were incubated at each 
bacterium’s optimum growth temperature as listed above. The zones of inhibition (ZOI) 
were measured after 24, 48, and 72 h. Three replicates were carried out for each nanoparticle 
treatment and bacterial strain. Experiment was repeated three times to ensure data 
reproducibility.
Determination of Minimum Inhibitory Concentrations (MICs)
MICs of nanoparticles were determined using a modified broth microdilution method.[44] 
Briefly, overnight bacterial cultures were adjusted to ≈105 CFU mL−1, and nanoparticles 
were serially diluted with sterile water to achieve a range of concentrations between 1011 to 
107 particles μL−1. In a 96-well microplate, 150 μL aliquots of adjusted bacterial cultures 
were mixed with 50 μL aliquots of different NPs. Bacteria suspended in MHB without 
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addition of nanoparticles served as a positive control, while MHB without bacterial 
inoculum and nanoparticles served as a negative control. The inoculated microplates were 
incubated at each bacterium’s optimum growth temperature, and the susceptibility of 
microorganisms to different NPs was assessed by measuring optical density at 600 nm. The 
results were expressed as % viability obtained through Equation (4)
(4)
Where OD is the optical density at 600 nm, t0 is the initial time 0 h, and t20 is the time after 
20 h of incubation.
For further verification of inhibition of bacterial growth, 10 μL of bacterial cultures treated 
for 20 h with different nanoparticles were plated on MHA and incubated at each bacterium’s 
optimum growth temperature for additional 20 h. The MIC refers to the concentration of 
NPs that completely inhibited bacterial growth. Each treatment had four replications and the 
experiment was repeated twice.
Viability Staining Assays
Bacterial viability was determined by using a LIVE/DEAD BacLight Bacterial Viability Kit 
staining kit (Life Technologies). Overnight bacterial cultures were centrifuged at 8500 rpm 
for 3 min, supernatants were removed and the bacterial cells were suspended in 0.9% NaCl 
at OD600 of 0.1 (≈108 CFU mL−1). Freshly prepared nanoparticles were diluted 1:10 with 
sterile water. The adjusted bacterial cultures were mixed with the diluted nanoparticles at a 
ratio of 3:1, and incubated at 20 °C in the dark. At 0, 2, 4, 6, 8, 12, and 24 h, 100 μL aliquots 
of the bacteria-NP mixtures were transferred into a black flat bottom microplate, and mixed 
with 100 μL of the LIVE/DEAD BacLight staining reagent. The samples were incubated in 
the dark for 15 min, and fluorescence was measured using a 485/20 nm excitation filter (for 
both SYTO9 and PI) and a 528/20 nm (SYTO9 emission wavelength) and a 620/40 nm (PI 
emission wavelength) emission filter. For confocal imaging, 5 μL of the stained sample was 
cast on a microscope slide. Each sample was assayed in triplicate, and the experiment was 
repeated twice. The results of viability staining were confirmed by plating 10 μL of each 
bacterial suspension on MHA, and incubating the plates at an appropriate growth 
temperature for 20 h.
Terminal Dilution Assays
To compare the rate of bacterial killing by different NPs, the test organisms were exposed to 
NPs and the decline in numbers of viable bacteria was followed by a modified terminal 
dilution method.[51] The bacterial cultures were prepared and adjusted to ≈108 CFU mL−1 as 
described above. The adjusted bacterial cultures (9 mL) were mixed with nanoparticles (1 
mL), and the bacterial populations were determined immediately after the addition of NPs (0 
h), and at 2, 4, 8, 12, and 24 h of exposure. At each time point, 100 μL aliquots of the 
bacteria-NP suspensions were transferred into 96 well microplates prefilled with 200 μL of 
MHB and serially diluted. The inoculated microplates were incubated for 48 h at an 
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appropriate growth temperature, after which the turbidity in each well was measured with a 
BioTek Synergy 2 microplate reader. An optical density at 600 nm of ≥0.05 was considered 
positive for bacterial growth. Populations of viable bacteria were calculated from the final 
dilution (terminal dilution, or TD), in which bacterial growth was observed using Equation 
(5)
(5)
Where TD is the terminal dilution factor obtained from microplate readings.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
a) The thiol-ene reaction involves alternating chain transfer and propagation b) with various 
multifunctional monomers used to generate polythioether nanoparticles via thiol-alkene 
photopolymerization in miniemulsion. c) Representative TEM of thymol/carvacrol-loaded 
nanoparticles.
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Figure 2. 
a) Amounts of essential oils extracted from the supernatant after pelleting NPs by 
ultracentrifugation. b) Calculated release profiles for both CNPs and TCNPs over 24 h.
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Figure 3. 
Well diffusion assay identifies treatments with antimicrobial activity. Bacteria were 
incubated with a) Hitenol BC-20 (70 × 10−3 M), b) ControlNPs, c) CNPs, and d) TCNPs at 
1013 NPs mL−1. Zones of inhibition (ZOI, mm) are reported below each image.
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Figure 4. 
Percent viability of various bacteria upon treatment with TCNPs. The 0 μg mL−1 EO {1011} 
was treated with ControlNPs. Inset images show the corresponding spot tests for the presence 
of live bacteria.
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Figure 5. 
Effect of TCNPs on the viability of a) B. subtilis ATCC 6633 and b) E. coli ATCC 25922, as 
monitored by confocal laser scanning microscopy. Representative images of control cultures 
(top row), and cultures treated with 1011 TCNPs (middle and bottom row) at the indicated 
time points. The green signal (SYTO 9) indicates viable live cells, whereas red signal 
(propidium iodide) indicates damaged or dead cells. Scale bars = 10 μm.
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Figure 6. 
Evaluation of antimicrobial activity for 1011 TCNPs mL–1 on the viability of (●) E. coli 
ATCC 25922, (■) S. aureus RN6390, (▲) B. subtilis ATCC 6633, (▼) E. coli ATCC 43895 
(serotype O157:H7), and (◆) B. cenocepacia K56-2 via a) a kinetic terminal dilution and b) 
percentage of bacteria killed and over 48 h. *Dashed line represents the limit of quantitation.
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Figure 7. 
a) TEM of E. coli ATCC 25922 and b) B. subtilis ATCC 6633 control cultures and cultures 
that were challenged with 1011 TCNPs for various times. c) High resolution SEM of the 
control culture of B. subtilis ATCC 6633 and the culture treated for 24 h with 1011 TCNPs.
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